|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
The Madrina Network Web Portal
|
3R44CA177037-03S1
|
$34,313
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Image-guided ultrasound ablation for precision targeting of prostate cancer
|
1R01CA230323-01
|
$580,217
|
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
5R21CA195433-02
|
$266,380
|
$266,380
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
1R43CA225169-01
|
$295,205
|
$295,205
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
1R43CA217502-01A1
|
$300,000
|
$201,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
$1,340
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
1R44CA224460-01
|
$299,805
|
$299,805
|
Daunch, William
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
$76,615
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-02
|
$520,564
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis
|
1R01CA222358-01A1
|
$635,306
|
$635,306
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Nutritionally Driven Sporadic Intestinal Tumors: Impact on Stem Cells
|
1R01CA229216-01
|
$493,238
|
$493,238
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-05
|
$660,173
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-06
|
$660,173
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-21
|
$380,585
|
$380,585
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Designing Novel Anti-Cancer Therapeutics: Targeting Methionine Metabolism
|
1F30CA210372-01A1
|
$49,044
|
$49,044
|
FIRESTONE, ROSS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-04
|
$346,525
|
$173,263
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
$437,537
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Next Generation of HPV and Cervical Cancer Research in HIV+ Women
|
1R01CA230331-01
|
$670,295
|
|
STRICKLER, HOWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
OPTION PERIOD 2- PATIENT ACCRUAL AND TREATMENT 12/30/2016-12/29/2017
|
261201500022C
|
$453,713
|
$453,713
|
UNKNOWN, UNKNOWN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
$138,610
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
$138,610
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
5R44CA199667-02
|
$835,665
|
$835,665
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
Exploiting the immune response to detect pathogen-induced cancers
|
5R01CA199948-03
|
$436,974
|
$436,974
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Multiplexed In Solution Protein Array (MISPA) for identifying novel protein interactions in cancer and for early detection of immune responses in pathogen-induced cancers
|
5R21CA196442-03
|
$201,623
|
$201,623
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
5R01CA201179-02
|
$650,269
|
$325,135
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Arizona Cancer and Evolution Center (ACE)
|
1U54CA217376-01A1
|
$1,906,167
|
$1,906,167
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Modeling Neoplastic Progression in Barrett's Esophagus
|
5R01CA140657-09
|
$350,952
|
$350,952
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
$299,983
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
Colon Cancer Chemoprevention with Phosphodiesterase-5 Inhibitors
|
5R01CA172627-05
|
$311,250
|
$311,250
|
BROWNING, DARREN
|
AUGUSTA UNIVERSITY
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-15
|
$307,800
|
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
P53 inactivation on MDSC development and tumor progression
|
5R01CA169133-05
|
$315,400
|
$315,400
|
CUI, YAN
|
AUGUSTA UNIVERSITY
|
|
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
|
5R01CA168912-04
|
$320,588
|
$320,588
|
HE, YUKAI
|
AUGUSTA UNIVERSITY
|
|
TREM-1 and Its Implications to Cancer
|
5R01CA172230-04
|
$315,400
|
$315,400
|
HORUZSKO, ANATOLIJ
|
AUGUSTA UNIVERSITY
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-08
|
$307,800
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-09
|
$307,800
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-04
|
$315,400
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-05
|
$315,400
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Novel Biomarkers for the Clinical Management of Bladder Cancer
|
1R01CA227277-01A1
|
$466,211
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-05
|
$341,059
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
Total relevant funding to Digestive Diseases for this search: $749,605,735
|